Products for Research Use Only

Cabozantinib-d4 (S-malate)

CAT: 0804-HY-W706452Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W706452Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cabozantinib-d4 (S-malate) (XL184-d4 (S-malate) ; BMS-907351-d4 (S-malate) ) is the deuterium labeled Cabozantinib (S-malate). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
Product Name Alternative
XL184-d4 (S-malate) ; BMS-907351-d4 (S-malate)
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; VEGFR
Related Pathways
Apoptosis; Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(NC(C([2H])=C1[2H])=C(C([2H])=C1OC2=CC=NC3=C2C=C(C(OC)=C3)OC)[2H])C4(C(NC5=CC=C(C=C5)F)=O)CC4.O[C@@H](CC(O)=O)C(O)=O
Molecular Formula
C32H26D4FN3O10
Molecular Weight
639.62
References & Citations
[1]Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res, 2011, 17 (12), 3943-3955.|[2]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71 (14), 4758-4768.|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10 (12), 2298-2308.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported